WITHDRAWNNA

Corneal Thinning During Topical Bevacizumab Therapy

NCT00515684•Yonsei University

Summary

The purpose of this study is to determine whether topical bevacizumab is safe or not when used in corneal neovascularization for long term period.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•clinical diagnosis of corneal neovascularization
•must be able to apply eyedrop

Exclusion Criteria

•have active keratitis

Locations (1)

Severance hospital

Seoul, South Korea

Key Dates

Start Date

May 1, 2007

Primary Completion Date

December 1, 2008

Completion Date

December 1, 2008

Last Updated

May 1, 2015

Conditions

Corneal Neovascularization

Interventions

bevacizumab (Avastin)

DRUG

Corneal Crosslinking for Treatment of Corneal Neovascularization

NCT04787471

Corneal Neovascularization

View study

COMPLETEDPHASE2/PHASE3

Prospective Study to Determine the Effect of Subconjunctival Bevacizumab (AVASTIN) in Corneal Neovascularization

NCT00555594

Corneal Neovascularization

View study

UNKNOWN

Correlation Between a Novel Subset of Neutrophil and Corneal Neovascularization.

NCT05659940

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 1, 2015Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Corneal NeovascularizationNeutrophils

View study

TERMINATEDPHASE1/PHASE2